In vivo safety testing of Antibody Drug Conjugates

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Antibody–Drug Conjugates: The Last Decade

(2020) Nicolas Joubert et al.   Pharmaceuticals

Acquired Resistance to Antibody-Drug Conjugates

(2019) Denis Collins et al.   Cancers

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

(2019) Steven Coats et al.   CLINICAL CANCER RESEARCH

Mechanisms Influencing The Disposition Of Monoclonal Antibodies And Peptides

(2019) Amita Datta-Mannan   DRUG METABOLISM AND DISPOSITION

Considerations for the Design of Antibody-Based Therapeutics

(2019) Dennis R. Goulet et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Immunogenicity of antibody–drug conjugates: observations across eight molecules in eleven clinical trials

(2019) Montserrat Carrasco-Triguero et al.   Bioanalysis

Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates: A review of recent advances and future perspectives

(2019) Kenichiro Todoroki et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Antibody-Drug Conjugates: A Comprehensive Review

(2019) Puregmaa Khongorzul et al.   MOLECULAR CANCER RESEARCH

An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates

(2019) Haleh Saber et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Antibodies to watch in 2020

(2019) Hélène Kaplon et al.   mAbs

Tutorial on Monoclonal Antibody Pharmacokinetics and its Considerations in Early Development

(2018) Meric Ovacik et al.   CTS-Clinical and Translational Science

Fate of Antibody-Drug Conjugates in Cancer Cells

(2018) Cécile Chalouni et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?

(2018) Kulmira Nurgali et al.   Frontiers in Pharmacology

A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists

(2018) Lars Mecklenburg   TOXICOLOGIC PATHOLOGY

Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium

(2018) Luca Falzone et al.   Frontiers in Pharmacology

Pharmaceutical industry perspective on combination toxicity studies: Results from an intra-industry survey conducted by IQ DruSafe Leadership Group

(2018) Joanne Birkebak et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

(2017) Joanna C. Masters et al.   INVESTIGATIONAL NEW DRUGS

Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors

(2017) Katerina T. Xenaki et al.   Frontiers in Immunology

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

(2017) Ricarda M. Hoffmann et al.   OncoImmunology

Antibody-drug conjugates for non-oncological indications

(2016) Renhe Liu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Antibody Drug Conjugates: Nonclinical Safety Considerations

(2015) Mary Jane Masson Hinrichs et al.   AAPS Journal

Impact analysis of ICH S9 on non-clinical development of anticancer drugs

(2015) Milton Bonelli et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

An FDA oncology analysis of antibody-drug conjugates

(2015) Haleh Saber et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality

(2014) M. Benjamin Hock et al.   AAPS Journal

Evaluation of genotoxicity testing of FDA approved large molecule therapeutics

(2014) Satin G. Sawant et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology

(2013) Stanley A. Roberts et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies

(2010) Carmel M. Lynch et al.   mAbs

Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals

(2010) Jay Tibbitts et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

ICH Guidelines: Inception, Revision, and Implications for Drug Development

(2010) Tao Wang et al.   TOXICOLOGICAL SCIENCES

Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

(2009) Mohammad Tabrizi et al.   AAPS Journal

Developmental toxicity testing of monoclonal antibodies: An enhanced pre- and postnatal study design option

(2009) Jane Stewart   REPRODUCTIVE TOXICOLOGY

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study

(2008) Jordi Rodon et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A History of Cancer Chemotherapy

(2008) Vincent T. DeVita et al.   CANCER RESEARCH